Banque Cantonale Vaudoise grew its holdings in DaVita Inc. (NYSE:DVA – Free Report) by 238.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,531 shares of the company’s stock after purchasing an additional 4,600 shares during the period. Banque Cantonale Vaudoise’s holdings in DaVita were worth $530,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of DVA. Captrust Financial Advisors grew its position in shares of DaVita by 3.7% in the first quarter. Captrust Financial Advisors now owns 3,860 shares of the company’s stock valued at $437,000 after purchasing an additional 139 shares during the last quarter. Sentry Investment Management LLC grew its position in DaVita by 63.4% during the fourth quarter. Sentry Investment Management LLC now owns 371 shares of the company’s stock worth $28,000 after buying an additional 144 shares in the last quarter. Parkside Financial Bank & Trust grew its position in DaVita by 88.6% during the first quarter. Parkside Financial Bank & Trust now owns 313 shares of the company’s stock worth $35,000 after buying an additional 147 shares in the last quarter. Wetherby Asset Management Inc. grew its position in DaVita by 8.1% during the first quarter. Wetherby Asset Management Inc. now owns 2,050 shares of the company’s stock worth $232,000 after buying an additional 154 shares in the last quarter. Finally, Comerica Bank grew its position in DaVita by 2.3% during the fourth quarter. Comerica Bank now owns 8,360 shares of the company’s stock worth $661,000 after buying an additional 187 shares in the last quarter. 83.78% of the stock is currently owned by hedge funds and other institutional investors.
DaVita Price Performance
Shares of NYSE:DVA opened at $100.77 on Wednesday. The firm has a market cap of $9.14 billion, a PE ratio of 18.59, a price-to-earnings-growth ratio of 1.03 and a beta of 0.93. The firm’s fifty day moving average is $96.05 and its 200-day moving average is $85.69. The company has a debt-to-equity ratio of 8.25, a quick ratio of 1.14 and a current ratio of 1.18. DaVita Inc. has a 52 week low of $65.28 and a 52 week high of $103.00.
Insider Buying and Selling at DaVita
In other DaVita news, Director Barbara J. Desoer sold 2,449 shares of the stock in a transaction that occurred on Wednesday, May 10th. The shares were sold at an average price of $101.61, for a total value of $248,842.89. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Kathleen Alyce Waters sold 15,941 shares of the stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $99.24, for a total value of $1,581,984.84. Following the transaction, the insider now owns 91,245 shares of the company’s stock, valued at approximately $9,055,153.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Barbara J. Desoer sold 2,449 shares of the stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $101.61, for a total transaction of $248,842.89. The disclosure for this sale can be found here. Insiders have sold a total of 37,502 shares of company stock worth $3,722,146 over the last three months. 1.40% of the stock is currently owned by insiders.
Analysts Set New Price Targets
A number of research firms recently weighed in on DVA. UBS Group lifted their target price on DaVita from $91.00 to $100.00 in a research report on Tuesday, May 9th. Truist Financial lifted their price objective on DaVita from $90.00 to $100.00 in a report on Tuesday, May 9th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of DaVita from $85.00 to $113.00 in a research note on Tuesday, May 9th. StockNews.com initiated coverage on shares of DaVita in a report on Thursday, May 18th. They set a “buy” rating for the company. Finally, TheStreet raised shares of DaVita from a “c” rating to a “b-” rating in a report on Monday, May 8th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, DaVita currently has a consensus rating of “Hold” and an average target price of $96.88.
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
- Five stocks we like better than DaVita
- Tesla Production Cranks Into High Gear, Shares Follow
- Ford Soars 30% YTD After Breaking Out: What’s Next?
- Acuity Brands Lights Up Opportunity In The Industrial Sector
- Overstock Looks Beyond Overbought After Bed Bath Re-Brand
- Tecnoglass Shines Bright As Analysts Bullish On Growth Potential
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
